Diabetic Neuropathy Market to Become Worth US $5.718 Billion by 2024
The vendor landscape of the world market for diabetic neuropathy is semi-consolidated wherein the leading market players have limited share. The competition amongst the already existing local and global producers of diabetic neuropathy drugs is fierce with much of the focus is on research and development work so as to offer improved neuropathy drugs sans the infections and complications that are associated with their use. Boehringer, for instance, has collaborated with Eli Lilly in an effort to come up with...
View full press release